Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Observational pilot study of Aloxi plus methylprednisolone for prevention of chemotherapy-induced nausea and vomiting in breast cancer
2006-005803-33Phase 4Active
- Sponsor
- Therabel
- Start
- Dec 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of palonosetron and methylprednisolone in chemotherapy-induced nausea and vomiting (CINV), sponsored by Therabel. Primary endpoint: Evaluation of nausea and vomiting. Started Dec 2006; status: active.
02
Drugs
palonosetronmethylprednisolone
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on 2006-005803-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005803-33.